Add New
    0
    Add New

    DiogenX

    DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). Its aim is to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world. The company was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France. DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.

    Description

    SHORT DESCRIPTION:

    DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). Its aim is to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world. The company was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France. DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.

     

    LONG DESCRIPTION:

    Based in

    Marseille

    Get Directions
    Nation
    Founded in

    2019

    Founding Status

    $ 2.5 Millions - $ 5 Millions

    Industries
    Follow us
    mood_bad
  • No comments yet.
    • Add a review

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    General Rating

    Products / Services

    Pricing

      You May Also Be Interested In

      error: Content protected